Does Rallies show 13F holders for ABBV?

Yes. Rallies tracks hedge fund and 13F ownership data for ABBV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ABBV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABBV. It does not provide personalized investment advice.

ABBV (AbbVie) Stock Analysis - Hedge Fund Holdings

AbbVie (ABBV) is a publicly traded Healthcare sector company. As of May 20, 2026, ABBV trades at $212.09 with a market cap of $369.98B and a P/E ratio of 104.75. ABBV moved -0.58% today. Year to date, ABBV is -6.78%; over the trailing twelve months it is +15.10%. Its 52-week range spans $163.81 to $244.81. Analyst consensus is strong buy with an average price target of $254.11. Rallies surfaces ABBV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ABBV stock?

Hedge funds tracked by Rallies that own ABBV include Panagora Asset, Berkshire Asset, Pinebridge Investments, Temasek Holdings, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AbbVie.

ABBV Key Metrics

Key financial metrics for ABBV
Metric	Value
Price	$212.09
Market Cap	$369.98B
P/E Ratio	104.75
EPS	$2.03
Dividend Yield	1.73%
52-Week High	$244.81
52-Week Low	$163.81
Volume	3.02M
Avg Volume	0
Revenue (TTM)	$62.82B
Net Income	$3.64B
Gross Margin	70.68%

Top Hedge Funds Holding ABBV

Panagora Asset holds 491.31K shares of ABBV, changed +78.41% as of Mar 31, 2026.
Berkshire Asset holds 380.87K shares of ABBV, changed +1.04% as of Mar 31, 2026.
Pinebridge Investments holds 83.01K shares of ABBV, changed -58.97% as of Sep 30, 2025.
Temasek Holdings holds 67.97K shares of ABBV, changed +60.03% as of Sep 30, 2025.
Bridgewater Associates holds 30.36K shares of ABBV, changed +113.68% as of Mar 31, 2026.

Latest ABBV News

DDW Reveals Risankizumab Lowers Steroid Use from 34% to 7% and Upadacitinib Reduces Hospitalizations 31% — May 5, 2026
AbbVie jumps as Q1 results drive raised 2026 profit outlook and key-drug momentum — Apr 30, 2026
Bank of America Raises AbbVie Price Target to $234, Allergan Aesthetics Pledges $100K Donation — Apr 30, 2026
AbbVie Raises 2026 Outlook to $14.28, Triggers $18M Oncology Milestone — Apr 29, 2026
AbbVie falls despite Q1 beat as Humira erosion and FDA CRL rattle sentiment — Apr 29, 2026

Recent ABBV Insider Trades

Purdue David Ryan sold 5.23K (~$1.22M) on Mar 4, 2026.
Siatis Perry C sold 5.78K (~$1.35M) on Mar 2, 2026.
Siatis Perry C sold 10.29K (~$2.41M) on Mar 2, 2026.

ABBV Analyst Consensus

20 analysts cover ABBV: 0 strong buy, 15 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $254.11.

Common questions about ABBV

Who owns ABBV stock?: Hedge funds tracked by Rallies that own ABBV include Panagora Asset, Berkshire Asset, Pinebridge Investments, Temasek Holdings, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for AbbVie.
Does Rallies show 13F holders for ABBV?: Yes. Rallies tracks hedge fund and 13F ownership data for ABBV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ABBV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABBV. It does not provide personalized investment advice.